Immunitybio Stock

Immunitybio EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Immunitybio (IBRX) as of Sep 5, 2026 is -18.18. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -16.21 — a change of 12.14% (lower).

EV/FCF

-18.18

YoY

12.14%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Immunitybio is 2026 -18.18 . EV/FCF (Enterprise Value to Free Cash Flow) of Immunitybio was 2025 -16.21 . It decreases by 12.14% lower compared to the previous year.

The Immunitybio EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-75.68 USD
Jan 1, 2019
-37.12 USD
Jan 1, 2020
-34.78 USD
Jan 1, 2021
-19.95 USD
Jan 1, 2022
-15.45 USD
Jan 1, 2023
-16.18 USD
Jan 1, 2024
-16.21 USD
Jan 1, 2025
-18.18 USD
The Immunitybio EV/FCF history
YEAREV/FCFYoY
-18.18+12.14%
-16.21+0.20%
-16.18+4.69%
-15.45-22.54%
-19.95-42.64%
-34.78-6.30%
-37.12-50.96%
-75.68+10.42%
-68.54-45.31%
-125.32-37.93%
-201.90-80.31%
-1,025.39
Access this data via the Eulerpool API

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunitybio stock

EV/FCF (Enterprise Value to Free Cash Flow) of Immunitybio is -18.18 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Immunitybio changed from -16.21 to -18.18, representing a 12.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Immunitybio since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Immunitybio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Immunitybio

All Key Metrics — Immunitybio